Related references
Note: Only part of the references are listed.FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin plus /- cetuximab
Janne B. Kjersem et al.
BMC CANCER (2014)
Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer
Woo-Jeong Jeong et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
NK cell-based immunotherapy for malignant diseases
Min Cheng et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2013)
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
James D. Mellor et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
IL-10 Conditioning of Human Skin Affects the Distribution of Migratory Dendritic Cell Subsets and Functional T Cell Differentiation
Jelle J. Lindenberg et al.
PLOS ONE (2013)
Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol
Ulrike Koehl et al.
FRONTIERS IN ONCOLOGY (2013)
IL-2-or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients
Maria P. Roberti et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
KRAS and BRAF Mutation Analysis in Routine Molecular Diagnostics Comparison of Three Testing Methods on Formalin-Fixed, Paraffin-Embedded Tumor-Derived DNA
Danielle A. M. Heideman et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2012)
Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome
Rosa Calemma et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Use of allogeneic NK cells for cancer immunotherapy
Melissa A. Geller et al.
IMMUNOTHERAPY (2011)
Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors
Luis G. Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process
Jan Spanholtz et al.
PLOS ONE (2011)
Human Leukocyte Antigen E Contributes to Protect Tumor Cells from Lysis by Natural Killer Cells
Elisa Lo Monaco et al.
NEOPLASIA (2011)
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Alberto Bardelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
High Log-Scale Expansion of Functional Human Natural Killer Cells from Umbilical Cord Blood CD34-Positive Cells for Adoptive Cancer Immunotherapy
Jan Spanholtz et al.
PLOS ONE (2010)
Decrease in intrahepatic CD56+lymphocytes in gastric and colorectal cancer patients with liver metastases
Maya Gulubova et al.
APMIS (2009)
Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment
Jaume Capdevila et al.
CANCER TREATMENT REVIEWS (2009)
Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells
Estrella Mariel Levy et al.
INNATE IMMUNITY (2009)
Natural killer cells kill human melanoma cells with characteristics of cancer stem cells
Gabriella Pietra et al.
INTERNATIONAL IMMUNOLOGY (2009)
Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
Frederic Bibeau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Defective Infiltration of Natural Killer Cells in MICA/B-Positive Renal Cell Carcinoma Involves β2-Integrin-Mediated Interaction
Guiseppe Sconocchia et al.
NEOPLASIA (2009)
Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56BrightCD16- cells and display an impaired capability to kill tumor cells
Paolo Carrega et al.
CANCER (2008)
Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
S. Arai et al.
CYTOTHERAPY (2008)
Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy
Liat Binyamin et al.
JOURNAL OF IMMUNOLOGY (2008)
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
W. De Roock et al.
ANNALS OF ONCOLOGY (2008)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
Silvia Benvenuti et al.
CANCER RESEARCH (2007)
Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines
Jun Kurai et al.
CLINICAL CANCER RESEARCH (2007)
Impact of EGFR expression on colorectal cancer patient prognosis and survival
JP Spano et al.
ANNALS OF ONCOLOGY (2005)
Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck
I Kuss et al.
CLINICAL CANCER RESEARCH (2004)
Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients
AG Menon et al.
LABORATORY INVESTIGATION (2002)
The biology of human natural killer-cell subsets
MA Cooper et al.
TRENDS IN IMMUNOLOGY (2001)
Share Paper
